ABSTRACT
Introduction Survival after critical illness has noticeably improved over the last decades due to advances in critical care medicine. Besides, there are an increasing number of elderly patients with chronic diseases being treated in the intensive care unit (ICU). More than half of the survivors of critical illness suffer from medium- or long-term cognitive, psychological and/or physical impairments after ICU discharge, which is recognized as post intensive care syndrome (PICS). There are evidence- and consensus-based quality indicators (QIs) in intensive care medicine, which have a positive influence on patients’ long-term outcomes if adhered to.
Methods and analysis The protocol of a multicentre, pragmatic, stepped wedge cluster-randomized controlled, quality improvement trial is presented. During three predefined steps, 12 academic hospitals in Berlin and Brandenburg, Germany, are randomly selected to move in a 1-way crossover from the control to the intervention condition. After a multifactorial training programme on QIs and clinical outcomes for site personnel ICUs will receive an adapted, interprofessional protocol for a complex telehealth intervention comprising of daily telemedical rounds at ICU. The targeted sample size is 1431 patients. The primary objective of this trial is to evaluate the effectiveness of the intervention on the adherence to 8 QIs daily measured during the patient’s ICU stay, compared to standard of care. Furthermore, the impact on long-term recovery such as PICS-related patient-centred outcomes including health-related quality-of-life, mental health, clinical assessments of cognition and physical function, all-cause mortality, and cost-effectiveness 3 and 6 months after ICU discharge will be evaluated.
Ethics and dissemination This protocol was approved by the ethics committee of the Charité Universitätsmedizin, Berlin, Germany (EA1/006/18). The results will be published in a peer-reviewed journal and presented at conferences. Study findings will also be disseminated via the website (https://www.eric-projekt.de).
Trial registration number ClinicalTrials.gov NCT03671447 (https://clinicaltrials.gov/ct2/show/NCT03671447, 22 August 2018)
Strengths and limitations of this study
▪ Telemedicine-based care potentially improves the adherence to quality indicators (QIs) in intensive care medicine, which accelerate patient recovery and improve long-term outcomes after critical illness.
▪ ERIC is the first large-scale cluster-randomized controlled trial to be carried out in ICUs in Berlin and Brandenburg, Germany, comparing the clinical and cost effectiveness of a telehealth-based quality improvement intervention to standard of care.
▪ By employing a stepped-wedge design, this quality improvement study will allow each cluster to act as its own control and preserve the internal validity of the study, with a potential for confounding by secular trends.
▪ The nature of the intervention does not allow blinding of study personnel and eligible patients at ICUs and might be confronted with cross-contamination and staff turnover.
▪ ERIC allows getting a comprehensive evaluation from the patient’s perspective, healthcare staff and health economics and assessing its suitability to become standard of care.
Competing Interest Statement
All authors report grants from the German Innovation Fund of the Federal Joint Committee (G-BA), during the conduct of the study. CS reports grants from Aridis Pharmaceutical Inc., grants from B. Braun Melsungen AG, grants from Drägerwerk AG & Co. KGaA, grants from Grünenthal GmbH, grants from Infectopharm GmbH, grants from Sedana Medical Ltd., grants from Deutsche Forschungsgemeinschaft / German Research Foundation, grants from Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR) / German Aerospace Center, grants from Einstein Stiftung Berlin/ Einstein Foundation Berlin, grants from European Society of Anaesthesiology, grants from Gemeinsamer Bundesausschuss / Federal Joint Committee (G-BA), grants from Inneruniversitäre Forschungsförderung / Inner University Grants, grants from Projektträger im DLR / Project Management Agency, grants from Stifterverband / Non-Profit Society Promoting Science and Education, grants from WHOCC, grants from Baxter Deutschland GmbH, grants from Biotest AG, grants from Cytosorbents Europe GmbH, grants from Edwards Lifesciences Germany GmbH, grants from Fresenius Medical Care, grants from Grünenthal GmbH, grants from Masimo Europe Ltd., grants from Medtronic GmbH, grants from Pfizer Pharma PFE GmbH, personal fees from Georg Thieme Verlag, grants from Dr. F. Köhler Chemie GmbH, grants from Sintetica GmbH, grants from European Commission, grants from Stifterverband für die deutsche Wissenschaft e.V. / Philips, grants from Stiftung Charité, outside the submitted work. In addition, CS has a patent 10 2014 215 211.9 pending, a patent Application No. PCT/EP2015/067730 pending to Graft Gesellschaft von Architekten mbH, and a patent Application No. PCT/EP2015/067731 pending to Graft Gesellschaft von Architekten mbH. BW reports personal fees from Orion Pharma Ltd., outside the submitted work.
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT03671447
Funding Statement
This project is funded by the German Innovation Fund ('New Forms of Care') of the Federal Joint Committee (G-BA), the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany (https://www.g-ba.de/english/). Following a competitive external peer review by the scientific advisory board, this study was awarded a grant in 2016 (reference number: 01NVF16011). The funding agency had no role in the development of the study design, collection, analysis, interpretation of data, manuscript development, or the decision to submit the manuscript for publication. The protocol is based on the project application, which received previous peer review as part of the grant funding process. Charité - Universitätsmedizin Berlin is the sponsor of the trial.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† A full list of collaborators of the ERIC study group including affiliations is included in the Supplementary Materials
E-mail addresses of co-authors claudia.spies{at}charite.de
Bjoern.Weiss{at}charite.de
nicolas.paul{at}charite.de
adrion{at}ibe.med.uni-muenchen.de
mansmann{at}ibe.med.uni-muenchen.de
elke.berger{at}tu-berlin.de
rbusse{at}tu-berlin.de
ursula.marschall{at}barmer.de
joerg.caumanns{at}fokus.fraunhofer.de
srosseau{at}klinikevb.de
† Group authorship for the collaborators of the ERIC study group: Collaborators are listed in the Supplementary file 1.
Supplementary Materials: Organizational structure of ERIC; TIDieR checklist; Statistical Methods;SPIRIT 2013 checklist;
Data Availability
Due to legal restrictions imposed by the EC and the data protection commissioner of the Charité - Universitätsmedizin Berlin, public sharing of individual deidentified participant data with other researchers or entities is not allowed. Requests may be sent to dai-researchdata{at}charite.de.
Abbreviations
- (S)AE(s)
- (serious) adverse event(s)
- (e)CRF
- (electronic) Case report form
- CCI
- Chronic critical illness
- DIVI
- German Interdisciplinary Society for Intensive Care Medicine
- EDC
- Electronic data capture
- EQ-5D-5L
- EuroQol 5 dimensions and 5 level version
- EQ-VAS
- EuroQol Visual analogue scale
- EC
- ethics committee
- ERIC
- Enhanced Recovery after Intensive Care
- FPF(L)V
- first patient first (last) visit
- G-BA
- Federal Joint Committee
- GDPR
- General Data Protection Regulation
- GP
- General Practitioner
- HGS
- Hand grip strength test
- ICH-GCP
- International conference for harmonisation (of technical requirements for pharmaceuticals for human use) − good clinical practice guideline
- ICU
- Intensive care unit
- IES-R
- Impact of Event Scale revised
- ITT
- Intention to treat
- LPF(L)V
- last patient first (last) visit
- mMRC
- Modified British Medical Research Council (Dyspnea Scale)
- PHQ
- Patient health questionnaire
- PICS
- Post intensive care syndrome
- PP
- per protocol
- PTSD
- Post-traumatic stress disorder
- QI
- Quality indicator
- QALY
- Quality-adjusted life year
- QoL
- Quality of life
- REDCap
- Research Electronic Data Capture
- SHI
- Statutory Health Insurance
- SPIRIT
- Standard Protocol Items: Recommendations for Interventional Trials
- SW-CRT
- Stepped wedge cluster randomized trial
- Tele-ICU
- telemedicine intensive care unit
- TIDieR
- Template for Intervention Description and Replication checklist
- TUG
- Timed Up and Go test
- VAS
- Visual analogue scale
- WHODAS
- WHO Disability Assessment Schedule
